Building Momentum with Completion of Patient Enrollment in 4 Late-Stage Trials Multiple Late-Stage Clinical Trial Data Catalysts in 2022:– Nyxol®...
Phase 3 DISRUPT study enrollment continues on course towards conducting interim futility analysis as anticipated in H1 2022YONKERS, N.Y., March...
$36.88 Million in cash as of December 31, 2021, provides runway into second half of 2023 and a strong cash...
CELEBRATION, Fla., March 24, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH), a specialty pharmaceutical company focused on the discovery and...
CHICAGO, March 24, 2022 (GLOBE NEWSWIRE) -- Vanqua Bio today announced that the company will participate in the Stifel 2022...
CUPERTINO, Calif., March 24, 2022 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH), (“Reviva” or the “Company”), a clinical-stage pharmaceutical...
NEW YORK, March 24, 2022 (GLOBE NEWSWIRE) -- Dante Labs, a global leader in genomics and precision medicine, announces the...
SAN DIEGO, March 24, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty...
Clinical trial programs advance to further assess psychedelic-assisted psychotherapy utilizing lead drug candidate MYCO-001DENVER, March 24, 2022 (GLOBE NEWSWIRE) --...
Company received corrected FDA advice letter for Phase III trial with vilobelimab in hidradenitis suppurativaPositive Phase IIa data reported with...
TORONTO, March 24, 2022 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic...
An Emerging Markets Sponsored Commentary ORLANDO, Fla., March 24, 2022 (GLOBE NEWSWIRE) -- In the world of emergent small cap...
Renew ‘Moonlight’ by Solei, CBN Vape Pen, Now Available Across Canada Solei Renew Moonlight CBN Solei Renew Moonlight CBNTORONTO, March...
New Features Aim to Help More Patients with Kidney Failure Receive an Organ Transplant CareDx AlloCare transplant app CareDx AlloCare...
WALTHAM, Mass., March 24, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (Nasdaq:APLS), a global biopharmaceutical company and leader in complement, today...
Fourth Quarter 2021 Revenue of $65.9 million and Full Year 2021 Revenue of $209.3 million, Reflecting 22% Quarterly and 159%...
Company to progress to second dose cohort in the MARVEL-1 study immediately, with first patient dosing expected in mid-2022 LONDON,...
Carson City, Nevada--(Newsfile Corp. - March 24, 2022) - Cell MedX Corp. (OTCQB: CMXC) ("Cell MedX" or the "Company"), a...
Clinical, technology and operations leadership veteran with a proven track record brings experience to Bloom's Operational Health and Health-Tech strategyVancouver,...
Expanded the Phase II/III LANCER clinical trial in patients with cardiovascular disease (CVD), or significant CVD risk factors, who are...
